Crinetics Pharmaceuticals Inc. (CRNX) has a key regulatory event coming up next month, which has the potential to significantly impact its stock price.
The company's lead asset is Paltusotine, the first once-daily, oral, selectively targeted somatostatin receptor type 2 agonist in development for the proposed treatment of people with acromegaly.
For comments and feedback contact: editorial@rttnews.com
April 24, 2026 15:15 ET Economics news flow was relatively light this week even as the conflict in the Middle East continued, raising concerns for policymakers. In the U.S., spending data, initial jobless claims and pending home sales were the highlights. Business confidence in the biggest euro area economy was in focus in Europe. Inflation data from Japan gained attention in Asia.